Realidad terapéutica de la psoriasis moderada-grave en España. Encuesta de opinión

Ferrándiz, 2001, Prevalence of psoriasis in Spain (Epiderma Project: phase I), J Eur Acad Dermatol, 15, 20, 10.1046/j.1468-3083.2001.00191.x Lodeiro C, Peña J, del Pozo J. Psoriasis. Guías Clínicas. Fisterra 2003. Disponible en: http://www.fisterra.com/guias2/psoriasis.asp. Puig, 2009, Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología, Actas Dermosifiliogr, 100, 277, 10.1016/S0001-7310(09)70821-X Sampogna, 2004, Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: A cluster analysis, J Invest Dermatol, 122, 602, 10.1046/j.0022-202X.2003.09101.x Fredriksson, 1978, Severe psoriasis-oral therapy with a new retinoid, Dermatologica, 157, 238, 10.1159/000250839 2000 Reich, 2007, Treatment goals in psoriasis, JDDG, 5, 566, 10.1111/j.1610-0387.2007.06343.x Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriatic artritis. J Am Acad Dermatol 2009 (in press) Callen, 2003, AAD consensus statement on psoriasis therapies, J Am Acad Dermatol, 49, 897, 10.1016/S0190-9622(03)01870-X Feldman, 2005, Decision points for the initiation of systemic treatment for psoriasis, J Am Acad Dermatol, 53, 101, 10.1016/j.jaad.2005.03.050 Lebwohl, 2005, A clinician's paradigm in the treatment of psoriasis, J Am Acad Dermatol, 53, S59, 10.1016/j.jaad.2005.04.031 Gamo, 2006, Terapia biológica y psoriasis, Actas Dermosifiliogr, 97, 1, 10.1016/S0001-7310(06)73342-7 Finlay, 2004, Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy, J Cutan Med Surg, 8, 310, 10.1007/s10227-005-0030-6 Reich, 2008, Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a metanalysis, Curr Med Res Opin, 24, 1237, 10.1185/030079908X291985 Krueger, 2005, Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase iii trial, Br J Dermatol, 153, 1192, 10.1111/j.1365-2133.2005.06948.x Unmet Needs in the Management of Plaque Psoriasis. Clinical Briefs 2009;18(1). [consultado 28/7/2009]. Disponible en: http://www.managedcaremag.com/supplements/0901_CB_Plaque_Psoriasis/CB_Plaque_Psoriasis_MC.pdf. Dubertret, 2006, European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey, Br J Dermatol, 155, 729, 10.1111/j.1365-2133.2006.07405.x Garduno, 2007, Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review, J Dermatolog Treat, 18, 223, 10.1080/09546630701271807 Ferrándiz Foraster, 2007, Impacto de la psoriasis en la Calidad de Vida relacionada con la salud, Med Clin (Barc), 128, 325, 10.1157/13099796 Ribera, 2005, Encuesta sobre la psoriasis realizada a dermatólogos españoles, Piel, 20, 107, 10.1016/S0213-9251(05)72240-1 Bhosle, 2006, Quality of life in patients with psoriasis, Health Qual Life Outcomes, 4, 35, 10.1186/1477-7525-4-35 Sharma, 2004, Hydroxyurea as an alternative therapy for psoriasis, Indian J Dermatol Venereol Leprol, 70, 13 Lebwohl, 2005, Psoriasis treatment: traditional therapy, Ann Rheum Dis, 64, ii83, 10.1136/ard.2004.030791 Zaragoza, 2010, Seguridad y eficacia de etanercept a largo plazo en el tratamiento de la psoriasis, Actas Dermosifiliogr, 101, 47, 10.1016/j.ad.2009.07.001